

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 2 8 2002

TECH CENTER 1600/2900

Applicant:

William E. KLUNK et al.

Title:

THIOFLAVIN DERIVATIVES FOR

USE IN ANTEMORTEM

DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID

DEPOSITION

Appl. No.:

09/935,767

Filing Date:

08/24/2001

Examiner:

D. L. Jones

Art Unit:

1645

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the restriction requirement set forth in an Office Action mailed July 23, 2002, Applicants hereby elect the Group XIII claims, relating compounds comprised of Structure D, wherein Z = S. Claims 1-43 also have been cancelled in favor of claims 44-130, which are added to simplify prosecution and to cover Structure D compounds wherein Z = S, per the original claims. Support for the new claims can be found throughout the specification, including in the original claims.

The action additionally communicates a requirement for election of species. In response, applicants elect the species of compounds under Structure D wherein $R^1 = H$, $R^2 = CH_3$, $R^3 - R^7 = H$, $R^8 = OR'$ (wherein R' = H), $R^9 - R^{10} = H$, $Y = NR^1R^2$, and Z = S. Claims 44, 57-60, 63-75, 77, 84, 106, 107, 111, 114, and 117-124 are drawn to the elected species; claims 45, 76, 90, and 125-130 cover the elected specie when at least one

carbon is a radioisotope. 08/26/2002 CCHAU1 00000115 190741 09935

01 FC:103

1800.00 OP 840.00 OP

02 FC:102 03 FC:104

10.00 CH

270.00 OP